{
    "clinical_study": {
        "@rank": "115813", 
        "arm_group": {
            "arm_group_label": "relapsed or refractory NK/T cell lymphoma with gemcitabine"
        }, 
        "brief_summary": {
            "textblock": "We retrospectively review patients with refractory or relapsed ENKL who received a\n      gemcitabine-containing regimen"
        }, 
        "brief_title": "Gemcitabine in NK/T Cell Lymphoma", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "NK/T Cell Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, T-Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  NK/T cell lymphoma\n\n          -  relapse or refractory disease\n\n          -  gemcitabine containing treatment\n\n        Exclusion Criteria:"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "15 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "relapsed or refractory NK/T cell lymphoma treated with gemcitabine conatining treatment"
            }
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01660568", 
            "org_study_id": "2012-07-043"
        }, 
        "intervention_browse": {
            "mesh_term": "Gemcitabine"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 11, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Samsung Medical Center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "Gemcitabine in Pretreated/Refractory NK/T Cell Lymphoma", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Overall response rate", 
            "safety_issue": "No", 
            "time_frame": "2012-May"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01660568"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Samsung Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Samsung Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "August 2012"
    }
}